← All trials
NCT05556746
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2023
- Primary completion
- Nov 30, 2024
- Completion date
- Jan 31, 2026
- First posted
- Sep 27, 2022
- Last posted
- Nov 16, 2022
- Enrollment
- 156
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOverall official - principal investigator
- Harvard UniversityReponsible party - principal investigator
- Haitian Group for the Study of Kaposi's Sarcoma and OpportunisticCollaborator
- Harvard UniversityCollaborator
- University of Cape TownCollaborator
- University of Cape TownOverall official - principal investigator
- Stellenbosch UniversityCollaborator
- University of Cape TownOfficial
- University of California, Los AngelesCollaborator
- Harvard UniversityOfficial
- Harvard UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.